Altria (MO)
NYSEConsumer StaplesTobaccoSnapshot 2026-09-04
$68.88-0.88%
Close 2026-09-04 · 1-day change
NYSEConsumer StaplesTobaccoSnapshot 2026-09-04
Research Workspace
Put MO beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Consumer Staples is in steady. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
Primary pillar under pressure — Grow smoke-free product sales to offset cigarette declines: EPS growth stalled (missed Q1/Q2 2026) vs target of sustained growth.
View ThesisRevenue is contracting — down about 1% over the past year.
View GrowthRanks among the strongest in its industry on quality — around the top 16%.
View QualityManagement screens strong on capital allocation, earnings delivery, the balance sheet, market reaction to earnings.
View ManagementExpectations look high — what the market is pricing in runs ahead of what analysts forecast.
View ValuationModerate volatility — typically moves about 1% a day.
View RiskAltria's growth in the oral nicotine segment must continue to justify its price. Revenue growth has been steady, with the latest quarter showing a slight miss. The stock trades at 12× P/E compared to a peer median of 17×, indicating it looks expensive on this basis. The market is pricing in more growth than forecast, suggesting expectations are full. A specific risk is the potential credibility hit if Altria cuts guidance after recently raising it. Peer multiples imply a price about 3% below where it trades (it looks expensive on this basis). Our read remains intact.
Trailing returns as of 2026-09-04. MO is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 14 analysts currently covering MO (as of Sep 2026).
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
Continue this research
Compare MO with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Free account required to save the handoff. No credit card.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| MO Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 11 valuation methods, at three horizons. As of 2026-09-04. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Tobacco — fair value, gap to price, and forward P/E.
Compare the value case
Put MO next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Advances: Return significant value to shareholders via dividends and share repurchases
Dividend increase supports shareholder value objective.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-09-04. EPS is implied from price ÷ P/E. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Below average on quality vs scored peers
A second lens on the 12-month fair value: for companies that score high on measured quality (profitability, balance-sheet safety, earnings stability), this read trusts more of today's profit margins instead of averaging them toward their multi-year history the way the headline number does. Shown alongside the fair value above, not in place of it. A diagnostic, not a price target or a buy/sell signal.
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
Advances: Return significant value to shareholders via dividends and share repurchases
Dividend increase supports shareholder value objective.
Advances: Advance smoke-free product portfolio expansion
Challenges FDA review supports smoke-free product portfolio expansion.
Legal action may delay product approvals impacting growth.
Legal action may delay product approvals impacting growth.
Legal action may delay product approvals impacting growth.
Dividend increase supports shareholder value objective.
Threatens: Advance smoke-free product portfolio expansion
Narrowing focus on nicotine pouches may hinder product expansion.
